Semaglutide vs. Tirzepatide
A plain-language, educational look at how these two GLP-1-class molecules differ by mechanism, brand names, and FDA-approval status, plus how legitimate telehealth access works.
By The GLP-1 Samples Desk · 8 min read · Updated 2026-06-14
Find your match.
Answer two quick questions — we'll point you to the GLP-1 provider that fits and what it actually costs.
Bottom line up front: semaglutide and tirzepatide are two different prescription molecules in the broader GLP-1 category. Semaglutide acts on a single receptor (GLP-1), while tirzepatide acts on two receptors (GIP and GLP-1). Both require a prescription and a consultation with a licensed provider — neither is available as a true "free sample" of medication without a clinician. This page explains the factual differences so you can have an informed conversation with a provider.
Each molecule is sold under different FDA-approved brand names for different approved uses, and both are also offered by some telehealth providers in compounded form. This article does not rank one as "better," does not predict results, and does not provide medical advice. It compares them on factual, verifiable attributes only.
For adults 18+. Prescription medications require a consultation with a licensed provider. This is not medical advice. Statements not evaluated by the FDA.
The short version
- Semaglutide is a single-receptor GLP-1 receptor agonist; tirzepatide is a dual GIP and GLP-1 receptor agonist (a different molecular class), per published pharmacology.
- Semaglutide is FDA-approved under the brand names Ozempic and Rybelsus (type 2 diabetes) and Wegovy (chronic weight management and certain additional approved uses); tirzepatide is FDA-approved under Mounjaro (type 2 diabetes) and Zepbound (chronic weight management and certain additional approved uses).
- Both molecules require a prescription and a consultation with a licensed provider — there is no legitimate way to obtain them as Rx "free samples" without a clinician.
- Legitimate, lower-cost access generally comes through telehealth consultations, manufacturer self-pay programs (such as NovoCare and LillyDirect), patient-assistance programs, and — where clinically appropriate and legally permitted — compounded versions through licensed pharmacies.
- Brand-name pricing, insurance coverage, and compounded availability change over time; always verify current details directly with the provider or manufacturer.
| Attribute | Semaglutide | Tirzepatide |
|---|---|---|
| Molecule class | Single-agonist: GLP-1 receptor agonist | Dual-agonist: GIP and GLP-1 receptor agonist |
| Receptors targeted | GLP-1 receptor | GIP receptor and GLP-1 receptor |
| FDA-approved brand names (type 2 diabetes) | Ozempic (injectable); Rybelsus (oral tablet) | Mounjaro (injectable) |
| FDA-approved brand name (chronic weight management) | Wegovy (injectable; also has certain additional FDA-approved uses) | Zepbound (injectable; also has certain additional FDA-approved uses) |
| Manufacturer | Novo Nordisk | Eli Lilly |
| Common formats discussed by telehealth providers | Injectable; oral tablet (brand Rybelsus); some providers offer compounded oral/sublingual formats | Injectable; some providers offer compounded oral formats |
| Prescription required | Yes — consultation with a licensed provider required | Yes — consultation with a licensed provider required |
| Manufacturer direct self-pay option | NovoCare (Novo Nordisk) lists self-pay options for certain brands (verify current) | LillyDirect (Eli Lilly) lists self-pay vial options for Zepbound (verify current) |
| Compounded versions offered by some providers | Yes, through some licensed telehealth providers (availability varies; verify) | Yes, through some licensed telehealth providers (availability varies; verify) |
Factual comparison of the two molecule classes. Mechanism and FDA-approval status only — no efficacy or outcome claims. Verify all current details at the source.
Find your match
30-sec finder
Question 1 of 6
What brings you here today?
The core difference: one receptor vs. two
The most important factual distinction between these two medications is how many receptors each one acts on. According to published pharmacology, semaglutide is a GLP-1 receptor agonist — it acts on a single receptor target, the glucagon-like peptide-1 (GLP-1) receptor.
Tirzepatide is a dual agonist, meaning it acts on two receptors: the glucose-dependent insulinotropic polypeptide (GIP) receptor and the GLP-1 receptor. Because of this, the two are sometimes described as belonging to different sub-classes within the broader "GLP-1" conversation, even though tirzepatide is commonly grouped under the GLP-1 umbrella in everyday usage.
This page describes mechanism and approval status only. It does not make claims about how much weight any person may lose, nor does it claim either molecule treats or cures any condition. Those are individual medical questions for a licensed provider.
Brand names and FDA-approval status
Each molecule is marketed under distinct, FDA-approved brand names, and the approved use depends on the specific brand and dose. The summary below reflects publicly stated FDA approvals; always confirm the current, official labeling with the manufacturer or your provider.
Semaglutide (Novo Nordisk):
- Ozempic — an injectable approved in connection with type 2 diabetes management.
- Rybelsus — an oral tablet form approved in connection with type 2 diabetes.
- Wegovy — an injectable approved for chronic weight management in eligible adults, and which has gained certain additional FDA-approved uses over time.
Tirzepatide (Eli Lilly):
- Mounjaro — an injectable approved in connection with type 2 diabetes management.
- Zepbound — an injectable approved for chronic weight management in eligible adults, and which has gained certain additional FDA-approved uses over time.
Brand availability, approved indications, and labeling can change. This is a directory and education site, not a prescriber — a licensed provider determines whether any medication is appropriate for you.
Compounded versions: what "compounded" means
Beyond the FDA-approved brand-name products, some licensed telehealth providers offer compounded semaglutide or tirzepatide. Compounded medications are prepared by licensed pharmacies and are not the same as FDA-approved branded products; they are not individually FDA-approved. Availability of compounded versions varies over time and by provider, and depends on regulatory conditions.
Whether a compounded option is appropriate, available, and legal in your situation is a question for a licensed provider and pharmacy. We list providers that publicly state they offer these options so you can evaluate them — we do not facilitate sourcing outside of a legitimate prescription and consultation.
How legitimate, lower-cost access actually works
People often search for "samples" or "free" GLP-1 medication. Because these are prescription drugs, the realistic and legitimate ways to lower cost or get started are:
- Telehealth consultations — a licensed provider evaluates eligibility and, if appropriate, prescribes. Many directory providers bundle the visit, medication, and shipping into a transparent monthly price.
- Manufacturer self-pay programs — for example, NovoCare (Novo Nordisk) lists self-pay options for certain brands, and LillyDirect (Eli Lilly) lists self-pay vial options for Zepbound. Verify current pricing directly.
- Patient-assistance and savings programs — manufacturers sometimes offer savings cards or assistance for eligible patients; eligibility rules apply.
- Insurance coverage — where a plan covers a brand for an approved use, a copay may be lower than cash price. Coverage varies widely by plan.
As illustrative, provider-attributed examples of transparent telehealth pricing (verify current figures at each source): some directory providers list compounded semaglutide starting around the high-$100s per month and compounded tirzepatide at higher monthly figures, while manufacturer-direct brand options (such as Zepbound vials via LillyDirect or brand Wegovy via NovoCare) are priced separately. Prices are presented as "starting at" or typical ranges only and change frequently.
Finding a legitimate provider
Our directory lists telehealth providers that are real and currently operating, with attention to price transparency and what each one actually offers. Examples include ShedRx (compounded semaglutide and tirzepatide plus brand options; compounded starting around $199/mo, with a separate subscription fee noted for brand Wegovy/Zepbound — verify current), Measured Health (care plans plus GLP-1 medications starting around $140/mo, brand options higher — verify current), Elevate Health (oral semaglutide promotional pricing from around $114/mo; injectable options higher; includes free blood work — verify current), GobyMeds (all-inclusive pricing, compounded semaglutide from around $169/mo — verify current), Henry Meds, Eden, and Ivim Health. For manufacturer-direct self-pay, see NovoCare (Wegovy) and LillyDirect (Zepbound vials).
All pricing above is provider- or manufacturer-attributed and may change — confirm the exact, current total at checkout before subscribing. Whether a specific molecule, brand, or format is right for you is a decision to make with a licensed provider.
For adults 18+. Prescription medications require a consultation with a licensed provider. This is not medical advice. Statements not evaluated by the FDA.
Questions, answered
Is tirzepatide the same as semaglutide?
No. They are two different molecules. Semaglutide is a single GLP-1 receptor agonist, while tirzepatide is a dual agonist that acts on both the GIP and GLP-1 receptors, per published pharmacology. They are also sold under different FDA-approved brand names and made by different manufacturers (Novo Nordisk for semaglutide; Eli Lilly for tirzepatide).
What are the brand names for each?
Semaglutide is marketed as Ozempic and Rybelsus (in connection with type 2 diabetes) and Wegovy (for chronic weight management, with certain additional FDA-approved uses). Tirzepatide is marketed as Mounjaro (in connection with type 2 diabetes) and Zepbound (for chronic weight management, with certain additional FDA-approved uses). Always confirm current approved labeling with the manufacturer or your provider.
Can I get a free sample of semaglutide or tirzepatide without a prescription?
No. Both are prescription medications and require a consultation with a licensed provider. There is no legitimate way to obtain the actual medication as a no-prescription "free sample." Legitimate ways to lower cost include telehealth consultations, manufacturer self-pay programs (such as NovoCare and LillyDirect), patient-assistance programs, and insurance coverage where applicable.
What is a compounded version, and is it FDA-approved?
Compounded semaglutide or tirzepatide is prepared by a licensed pharmacy and is not the same as the FDA-approved branded product; compounded medications are not individually FDA-approved. Some licensed telehealth providers offer compounded options, but availability varies over time and depends on regulatory conditions. Whether a compounded option is appropriate and legally available in your situation is a question for a licensed provider and pharmacy.
Which one is better for weight loss?
This page does not rank one molecule as better or predict outcomes for any individual — that would be a medical and personal question. We compare the two only on factual attributes such as mechanism, brand names, FDA-approval status, and available formats. A licensed provider can discuss what may be appropriate for your specific situation.
How much do they cost through telehealth?
Pricing varies widely by provider, molecule, format (brand vs. compounded), and whether insurance is used. Directory providers publish prices as "starting at" figures — for example, some list compounded semaglutide in the high-$100s per month and compounded tirzepatide higher — while manufacturer-direct brand options are priced separately. All figures are provider- or manufacturer-attributed and change frequently, so confirm the current total at the source before subscribing.